Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Eribulin mesylát v léčbě pacientů s lokálně pokročilým nebo metastatickým karcinomem urotelu a dysfunkcí ledvin

10. listopadu 2026 aktualizováno: National Cancer Institute (NCI)

Fáze I/II studie analogu E7389 Halichondrin B (NSC č. 707389) u metastatického karcinomu uroteliálního traktu a renální insuficience

This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.

Přehled studie

Detailní popis

PRIMARY OBJECTIVES:

I. To establish whether eribulin mesylate (E7389) can be given safely to patients with moderate and severe renal dysfunction at 1.4 mg/m^2/week (the maximum tolerated dose [MTD] previously defined for patients with normal renal function) on days 1 and 8 of a 21-day cycle. (Phase I) II. To characterize the pharmacokinetic (PK) profile of E7389 in patients with moderate and severe renal dysfunction. (Phase I) III. To determine the response rate of patients with advanced urothelial carcinomas to E7389 in the first-line setting. (Phase II) IV. To determine the 6-month, progression-free survival and overall survival of patients with advanced urothelial carcinomas treated with E7389. (Phase II) V. To document the toxicity associated with the administration of E7389 to patients with advanced urothelial carcinoma patients and varying degrees of renal dysfunction. (Phase II) VI. To determine the response rate of patients with advanced urothelial carcinomas to E7389 in the setting of progression after prior platinum-based chemotherapy for advanced or recurrent disease, in two cohorts: tubulin-inhibitor treated or tubulin-inhibitor naive. (tubulin inhibitors in common use for urothelial cancer include paclitaxel, docetaxel and vinblastine). (Phase II) (per Amendment 6) VII. To determine the 6-month progression-free survival and overall survival of patients with advanced urothelial carcinomas treated with E7389 after platinum-based therapy for recurrent or advanced disease. (Phase II) (per Amendment 6) VIII. To document the toxicity associated with the administration of E7389 to patients with advanced urothelial carcinoma patients in the second line and later setting. (Phase II) (per Amendment 6) IX. To compare men and women with advanced bladder cancer treated with E7389 with respect to toxicity of E7389 as classified by Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 for (i) all hematologic toxicities, (ii) all non- hematologic toxicities, and (iii) the most frequently observed toxicities (neutropenia, anemia, leucopenia, infection). (Enrollment to additional females) (per Amendment 11) X. To compare men and women with advanced bladder cancer treated with E7389 with respect to response to E7389 as evidenced by (i) disease control rate (DCR) defined as stable disease (SD)+partial response (PR)+complete response (CR) at 12 weeks, (ii) progression-free survival (PFS), and (iii) overall survival (OS). (Enrollment to additional females) (per Amendment 11) XI. To compare men and women with advanced bladder cancer treated with E7389 with respect to pharmacokinetics of E7389. (Enrollment to additional females) (per Amendment 11) XII. To compare men and women with advanced bladder cancer treated with E7389 with respect to tumoral expression of genes involved in the mechanism of action of E7389, including tubulin isotypes, microtubule-associated protein 4 (MAP4), and stathmin. (Enrollment to additional females) (per Amendment 11)

OUTLINE:

Patients receive eribulin mesylate intravenously (IV) over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up monthly for 12 months and then every 3 months for up to 24 months.

Typ studie

Intervenční

Zápis (Aktuální)

168

Fáze

  • Fáze 2
  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • California
      • Beverly Hills, California, Spojené státy, 90211
        • Tower Cancer Research Foundation
      • Duarte, California, Spojené státy, 91010
        • City of Hope Comprehensive Cancer Center
      • Lancaster, California, Spojené státy, 93534
        • City of Hope Antelope Valley
      • Los Angeles, California, Spojené státy, 90033
        • USC / Norris Comprehensive Cancer Center
      • Martinez, California, Spojené státy, 94553-3156
        • Contra Costa Regional Medical Center
      • Martinez, California, Spojené státy, 94553
        • Veterans Administration Hospital - Martinez
      • Sacramento, California, Spojené státy, 95817
        • University of California Davis Comprehensive Cancer Center
      • South Pasadena, California, Spojené státy, 91030
        • City of Hope South Pasadena
    • Illinois
      • Chicago, Illinois, Spojené státy, 60637
        • University of Chicago Comprehensive Cancer Center
      • Decatur, Illinois, Spojené státy, 62526
        • Decatur Memorial Hospital
      • Evanston, Illinois, Spojené státy, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Harvey, Illinois, Spojené státy, 60426
        • Ingalls Memorial Hospital
      • Joliet, Illinois, Spojené státy, 60435
        • Duly Health and Care Joliet
      • Maywood, Illinois, Spojené státy, 60153
        • Loyola University Medical Center
      • Peoria, Illinois, Spojené státy, 61615
        • Illinois CancerCare-Peoria
      • Springfield, Illinois, Spojené státy, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Spojené státy, 62702
        • Central Illinois Hematology Oncology Center
    • Indiana
      • Fort Wayne, Indiana, Spojené státy, 46845
        • Fort Wayne Medical Oncology and Hematology Inc-Parkview
      • Kokomo, Indiana, Spojené státy, 46904
        • Community Howard Regional Health
      • South Bend, Indiana, Spojené státy, 46628
        • Northern Indiana Cancer Research Consortium
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48109
        • University of Michigan Rogel Cancer Center
      • Detroit, Michigan, Spojené státy, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Saint Joseph, Michigan, Spojené státy, 49085
        • Oncology Care Associates PLLC
    • Missouri
      • St Louis, Missouri, Spojené státy, 63141
        • Mercy Hospital Saint Louis
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Spojené státy, 15232
        • UPMC Hillman Cancer Center
    • Wisconsin
      • Milwaukee, Wisconsin, Spojené státy, 53226
        • Medical College of Wisconsin

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Patients must have locally advanced or metastatic urothelial cancer that is not amenable to surgical treatment
  • Patients must have histologically or cytologically confirmed urothelial tract carcinoma
  • Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan
  • All patients may have received up to two prior lines of chemotherapy for recurrent/advanced disease
  • Patients must have received at least one platinum-based chemotherapy for recurrent/advanced disease; recurrent disease is defined as having recurred after definitive therapy and advanced disease is defined as T4 and/or N2 and/or M1; in addition, for completion of Cohort #2, patients must also have received a tubulin inhibitor as part of their therapy for urothelial cancer; for purposes of this evaluation, treatment with chemotherapy regimens where carboplatin or similar is substituted for cisplatin or where a taxane is added or removed will be considered the same regimen; tubulin inhibitors in common use include paclitaxel, docetaxel, and vinblastine; the exception to this requirement applies to women
  • Women with and without prior therapy are also eligible; priority will be given to those who consent to participating in the pharmacokinetic studies
  • Life expectancy of greater than 6 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and Karnofsky >= 60%
  • Absolute neutrophil count >= 1,000/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 9 g/dL
  • Total bilirubin =< 1.5 institutional upper limit of normal (IULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X IULN
  • Patients must have either (a) normal kidney function (i.e. creatinine =< 1.5 X upper limit of normal [ULN] OR calculated creatinine clearance >= 60 mL/min by the modified Cockcroft and Gault Formula OR a creatinine clearance >= 60 mL/min obtained from a 24-hour urine collection) or (b) moderate or severe renal dysfunction (i.e. creatinine clearance < 60 mL/min and >= 20 mL/min)
  • Patients with symptomatic uremia, uncontrolled edema or unstable serum electrolytes should not enter the trial until such time as they have been stabilized - such patients should be discussed with the principal investigator
  • Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of E7389 Halichondrin analog will be determined following review of their case by the principal investigator
  • The effects of E7389 Halichondrin analog on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because tubulin inhibitors are known to be teratogenic, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Patients must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients may not be receiving any other investigational agents
  • Patients with brain metastasis that are unstable (i.e. presenting with neurologic symptoms that progress or require increasing doses of steroids within a 4-week period) or are untreated (i.e. not radiated) should be excluded
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because E7389 Halichondrin analog is tubulin inhibitor agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with E7389 Halichondrin analog, breastfeeding should be discontinued if the mother is treated with E7389
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with E7389 Halichondrin analog; HIV-positive patients with CD4+ =< 500/mm3 are ineligible because they are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in this group of patients when indicated
  • Prior therapy with E7389 Halichondrin analog (eribulin)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Treatment (eribulin mesylate)

Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Correlative studies

Correlative studies

Given IV

Ostatní jména:
  • Halaven
  • E7389
  • B1939 mesylát
  • Halichondrin B analog
  • ER-086526 mesylát

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Maximum Tolerated Dose (MTD) of Eribulin Mesylate for Patients Who Have Received a Tubulin-inhibitor for the Recurrent/Advanced Disease (Phase I)
Časové okno: 21 days

MTD will be graded according to Common Terminology Criteria for Adverse (CTCAE) version 5.0.

21 days
MTD of Eribulin Mesylate for Patients Who Have Not Received a Tubulin-inhibitor for the Recurrent/Advanced Disease (Phase I)
Časové okno: 21 days

MTD will be graded according to CTCAE version 5.0.

21 days
Number of Subjects With Overall Response
Časové okno: Up to 6 months

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): Complete Response (CR), Disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions; Overall Response (OR) = CR + PR

Up to 6 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression-free Survival (Phase II)
Časové okno: From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed at 6 months

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.1), as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, and appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed at 6 months
Progression-free Survival (Phase II)
Časové okno: From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed up to 12 months

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.1), as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, and appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed up to 12 months
Overall Survival (Phase II)
Časové okno: From the start of treatment on day 1 until death, assessed up to 12 months

Overall survival will be summarized as time from the start of treatment until death from any cause.

From the start of treatment on day 1 until death, assessed up to 12 months
Number of Participants With Adverse Events (AE)
Časové okno: Up to 24 months, or until the patient dies or refuses further follow up.

Graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. All observed toxicities (excluding unrelated or unlikely related AEs) will be summarized from the start of treatment until the end of treatment visit up to 24 months, or until the patient dies or refuses further follow up.

Up to 24 months, or until the patient dies or refuses further follow up.

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Pharmacokinetic Parameters for Eribulin Mesylate
Časové okno: At baseline; at 5, 10, 15, and 30 minutes; and at 1, 2, 4, 6, 8, 12, and 24 hours on day 1 of course 1 and at end of days 2-4 and 8 of course 1

Analyzed using compartmental and non-compartmental models. max concentration, systemic clearance, renal clearance, volume of distribution, half life, and area under the curve tabulated overall, and by prior exposure to tubulin-inhibitors, with summary statistics (means and standard deviations, or medians and ranges) and displayed with box-plots; the relationship between the PK parameters and indices of renal function (e.g. serum creatinine and creatinine clearance) will be examined using scatterplots and correlations.

At baseline; at 5, 10, 15, and 30 minutes; and at 1, 2, 4, 6, 8, 12, and 24 hours on day 1 of course 1 and at end of days 2-4 and 8 of course 1
Expression Levels of the Tubulin Isotypes
Časové okno: Baseline

For each of the tubulin isotypes, the distribution of the expression levels will be summarized with plots and standard statistical summary numbers; prior to analysis, the expression levels may be transformed to render the distributions more compatible with the assumptions of normal distribution. The association between the expression levels and response will be summarized with means and standard deviations and confidence intervals (or medians and ranges) and displayed with box-plots.

Baseline
Disease Control Rate (Complete Response [CR] + Partial Response [PR] + Stable Disease [SD])
Časové okno: 12 weeks

Logistic regression will be used to compare males and females, adjusting for the PK variables as well as age, renal status, and prior therapy.

12 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: David I Quinn, City of Hope Medical Center

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

23. října 2006

Primární dokončení (Aktuální)

9. července 2025

Dokončení studie (Odhadovaný)

9. července 2027

Termíny zápisu do studia

První předloženo

16. srpna 2006

První předloženo, které splnilo kritéria kontroly kvality

16. srpna 2006

První zveřejněno (Odhadovaný)

17. srpna 2006

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

13. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. listopadu 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • NCI-2009-00170
  • N01CM62201 (Grant/smlouva NIH USA)
  • P30CA033572 (Grant/smlouva NIH USA)
  • N01CM62209 (Grant/smlouva NIH USA)
  • U01CA062505 (Grant/smlouva NIH USA)
  • N01CM00071 (Grant/smlouva NIH USA)
  • UM1CA186717 (Grant/smlouva NIH USA)
  • N01CM00038 (Grant/smlouva NIH USA)
  • UM1CA186705 (Grant/smlouva NIH USA)
  • NCI-2009-00170 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
  • CDR0000492014
  • PHII-75
  • 7435 (Jiný identifikátor: CTEP)
  • 7435 (Jiný identifikátor: City of Hope Comprehensive Cancer Center)

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit